Although gastric cancer is quite common in Korea, the treatment outcome is relatively favorable compared to those in western countries. However, there are currently no Korean multidisciplinary guidelines for gastric cancer. Experts from related societies developed guidelines de novo to meet Korean circumstances and requirements, including 23 recommendation statements for diagnosis (n=9) and treatment (n=14) based on relevant key questions. The quality of the evidence was rated according to the GRADE evidence evaluation framework: the evidence levels were based on a systematic review of the literature, and the recommendation grades were classified as either strong or weak. The applicability of the guidelines was considered to meet patients' view and preferences in the context of Korea. The topics of the guidelines cover diagnostic modalities (endoscopy, endoscopic ultrasound, and radiologic diagnosis), treatment modalities (surgery, therapeutic endoscopy, chemotherapy, and radiotherapy), and pathologic evaluation. An external review of the guidelines was conducted during the finalization phase.
Literature search, evaluation, and preparation of recommendations
The fundamental and important issues concerning gastric cancer diagnosis and treatment were selected as key questions according to the patient, intervention, comparator, and outcome (PICO). Search terms for each respective key question were selected according to the medical subject headings (MeSH) terms of National Library of Medicine. For each key question, the inclusion/exclusion criteria were determined and the search words were properly combined to conduct the literature search. PubMed, MEDLINE and the Cochrane Library were used for the international literature search, while KoreaMed was used for the purpose of domestic literature search. The literature search was conducted only for the documents published from 1980~2011 in either English or Korean.
To evaluate the validity of the documents selected as evidence, a systematic and consistent evaluation method was adopted. In order to apply different evaluation methods, the documents were classified according to the study design. 3 To evaluate randomized controlled studies, the risk of bias (ROB) method of Cochrane Collaboration was adopted. 4 The Review Manager (RevMan) 5 (The Nordic Cochrane Centre, The Cochrane Collaboration, 2012) and GRADEpro program (Jan Broeck, Andrew Oxman, Holger Schünemann, 2008) were used to arrange the evidence and evidence summary table. 5 To evaluate non-randomized controlled studies, the NewcastleOttawa evaluation scale was applied. To evaluate diagnostic studies, the Quality Assessment of Diagnostic Accuracy Studies (QUADAS)
tool was used; 6 accordingly, the evaluations were classified as 'yes', 'no', or 'not clear' for 11 assessable items among the 14 items.
The Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) method was used for the evidence summary. 7, 8 Levels of evidence of studies were ranked according to the type of research, with a high level evidence for randomized clinical trials and a low level evidence for observational studies. Next, the qualitative level of the corresponding study was increased or decreased after considering the factors that influenced the quality of each study. The levels of evidence were classified as high-quality, A;
moderate-quality, B; low-quality, C; and very low-quality, D. For cases with no evidence or difficult to analyze, a fifth classification (no evidence or difficult to analyze, E) was added and used (Table 1) .
For the grading of recommendations, (1) a balance of desirable and undesirable effects, (2) evidence quality, and (3) values and preferences were taken into account, according to the GRADE method. Any area with difficult-to-determine recommendations is not mentioned in the present guideline, but will be reviewed during the next guideline development. The grades of recommendations are divided into (1) strong recommendations and (2) weak recommendations (Table 1) . A strong recommendation indicates that it is strongly recommended for most patients because compliance with this recommendation for a specific intervention will result in a desirable rather than an undesirable effect, along with a high quality of evidence and a better value and preference, compared to other interventions. A weak recommendation indicates that it is better for many patients to comply with this recommendation because despite rather weak evidence, a desirable effect has been shown. With a weak recommendation, some patients or medical staff might select different interventions according to the values or preferences.
Review and approval process
Based on the present guideline as developed by the Develop- 
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The present guideline was prepared as a designated project as- To achieve the best results, endoscopy should be performed by properly trained endoscopists using appropriate endoscopic devices.
Biopsy is necessary because there are limitations to the sensitivity and specificity of direct observation for diagnosing gastric cancer. 9 Normally, acquisition of more than 4 tissue samples is recommended in order to increase the diagnostic accuracy. However, a fewer number of samples might be enough in patients considering endoscopic resection. Biopsy has a low sensitivity for detecting Borrmann type IV advanced gastric cancers. Endoscopic clips or dye injection can be used to determine the resection margin during the surgery. 10 If it is difficult to localize the cancer lesion, as in rare cases, an intraoperative endoscopy can be performed. 
2) Chromoendoscopy
Chromoendoscopy is easy and simple method that allows better visualization of the lesions with unclear color changes or minute surface irregularities. It is also useful in determining the lateral borders during endoscopic submucosal dissection (ESD). Dyes include methylene blue, indigocarmine, acetic acid, and crystal violet, and among them, indigo carmine is the most commonly used. 12 After indigocarmine spraying, the dye fills the depressed mucosal sites, thus highlighting the surface irregularities. Such characteristics can help to estimate the depth of invasion of early gastric cancers (EGCs) and to determine the range of resection for endoscopic therapies.
Recommendation: Chromoendoscopy is useful in the determination of the lateral margin during endoscopic resection of early gastric cancer (Recommendation Grade 2, Evidence Level E). However, the sensitivity and specificity for detecting lymph node metastases were lower (0.69 and 0.84, respectively). 13 According to a recent Korean study, 14 which compared the accuracies of white light endoscopy and EUS, the accuracy of white light endoscopy for predicting the depth of invasion of EGCs was 73.7%, while that of EUS was only 67.4%. Therefore, the usefulness of endoscopic ultrasonography before endoscopic therapy for gastric cancer remains controversial.
Endoscopic ultrasonography
Recommendation: In some patients, endoscopic ultrasonography (EUS) is useful in addition to white light endoscopy and CT before endoscopic or surgical resection of gastric cancer (Recommendation Grade 2, Evidence Level D).
Radiology 1. Upper gastrointestinal series
The upper gastrointestinal series is a radiologic test that is widely used for the diagnosis of gastric cancer as it is safe and noninvasive without the need for specific preparation. It is useful as a preoperative test because of its high sensitivity and the ability to visualize the lesion location accurately and objectively. 15, 16 To perform an upper gastrointestinal series, it is important to obtain appropriate mucosal coating and gastrointestinal distention. For this purpose, a 240% weight per volume (w/v) high-density barium solution is generally used in gastrointestinal series. To ensure the accuracy of the upper gastrointestinal series, a single-contrast study including the compression and mucosal relief views should be combined with a double-contrast study that uses a high concentration of barium to coat the mucosa via air distention. 
Computed tomography
From the late 1970s, computed tomography (CT) is a diagnostic and preoperative test for detecting gastrointestinal tumors including gastric cancer. To date, special CT techniques for evaluating the stomach have been widely used to detect and diagnose gastric cancers, to determine the optimal treatment method via accurate staging, and to identify therapeutic effects after surgery or anticancer treatments. After the multidetector row CT (MDCT) was introduced, the diagnostic accuracy has increased and the detection of small lesions, including EGCs, has improved.
1) Multidetector row computed tomography
After the introduction of MDCT, the z-axis resolution improved, and thus the ambiguity of lesions due to partial volume averaging, which was considered as the disadvantage of conventionaltype single-channel helical CT, was decreased.
When using MDCT to diagnose gastric cancer, according to related literatures, at least a 4-channel MDCT is required, with a detector collimation ≤2.5 mm, an imaging section thickness ≤5 mm, and the administration of approximately 500 ml of water or an effervescent agent; the patient is then instructed to change position until each part of the stomach is properly distended. [18] [19] [20] Additionally, it is better to perform dynamic CT after contrast enhancement because arterial-phase imaging allows easy detection of enhanced mucosal lesions of the stomach, while portal venous-phase imaging provides more accurate information including the depth of invasion of gastric cancer and the involvement of adjacent organs and facilitates the evaluation of lymph node metastases. In addition, delayedphase imaging might also be useful because in some cases there is enhanced fibrosis surrounding the gastric cancer, thus allowing a more accurate evaluation of tumor infiltration into the gastric wall.
The reconstruction of arterial-phase and portal venous-phase images will permit CT angiography, which provides preoperative evaluation of perigastric blood vessels.
Upon examining the reports of preoperative tumor node metastasis (TNM) staging via MDCT, the accuracies ranged from 67.9%
to 90.9% for T (median value, 82.1%) and from 56.9% to 86% for N (median value, 69.5%). In particular, the specificity for T4, which determines whether surgery is indicated, ranged from 81.8% to 99.4% (median value, 96.5%). 18, [20] [21] [22] [23] [24] Nevertheless, CT allows clinicians to diagnose advanced gastric cancer that has spread to the peritoneum or shows distant metastases, thereby preventing unnecessary surgeries.
CT is also useful for evaluating the therapeutic effects after an- 27 In a study on the diagnosis of advanced gastric cancer, the success rate of PET in establishing the diagnosis ranged from 62% to 98% because FDG uptake varies according to the characteristics of gastric cancer. [28] [29] [30] [31] For example, PET/CT shows strong FDG uptake in the intestinal type gastric cancer and demonstrates high sensitivity, while a relatively low sensitivity was reported in diffuse-type tumors with a low level of FDG uptake. 32 Considering the above findings, endoscopy and barium upper gastrointestinal series are still considered to be more effective for diagnosing EGC.
Staging and prediction of prognosis
FDG PET/CT has a limited role in the detection of early primary gastric cancers. However, this is the same as that with contrast-enhanced CT, because it is difficult to evaluate primary tumors accurately due to the characteristics of the stomach. Additionally, according to the pathologic evaluation of biopsies, the cell densities and the degree of malignancies are not uniform; 32, 33 and therefore although PET/CT allows evaluation of the degree of metabolic activity and targets the highly malignant areas, its role is still limited with regard to accurate measurement of the depth of invasion into the gastric wall.
Next, when evaluating invasion into adjacent lymph nodes, the ability of PET to evaluate glucose metabolism is expected to allow more accurate detection of metastases to the local lymph nodes.
According to Mochiki et al., 31 the diagnostic performance of PET for N1 lymph nodes is not satisfactory, but this might have little clinical significance because these lymph nodes will be resected during gastric cancer surgery. On the other hand, invasion of lymph nodes in the N3 group is classified as distant metastasis, and it is very important to determine distant metastasis accurately. Yun et al. 34 reported that PET might provide useful information on distant lymph node invasion.
In a study by Hillner et al. 35 of 3,025 gastric cancer patients, distant metastases to other internal organs was evaluated, and patient management was altered significantly after the PET results in 37% of cases and PET showed better results than the conventional tests in the detection of liver metastases. 36 In terms of skeletal evaluation, bone scanning still plays an important role and PET scanning can play a compensatory role in the detection of osteolytic bone metastasis. 29 In PET scanning, the degree of FDG uptake in primary gastric cancer is expected to be an additional predictive factor along with the conventional anatomical imaging-adapted TNM staging. 32, 33 Additionally, peritoneal metastasis is also one of the important prognostic factors of gastric cancer and PET has a higher specificity (99%), lower sensitivity (35%), and equal accuracy when compared to CT for detection of peritoneal metastasis. 
Evaluation of recurrence
Postoperative evaluation of recurrence is very important in the management of gastric cancer. Sites of gastric cancer recurrence include adjacent organs, lymphatic system, blood circulation, and peritoneum. Consequently, recurrence sites include the local area, liver, lungs, skeletal system, peritoneum, and many other sites.
Changes in the anatomical structure after gastric surgery can make it difficult to diagnose recurrence accurately in many cases. Some studies have reported that PET is better than conventional CT in terms of specificity and positive predictive value. 33, 38 Several studies reported that PET scanning after gastric distension due to water intake is useful for determining postoperative recurrence. 39 According to the recent studies that assessed PET/CT, PET generally provides better results for the evaluation of gastric cancer recurrence compared to contrast-enhanced CT 40 and this might be due to the combination of anatomic and functional data. 
Determination of therapeutic effects
During gastric cancer therapy, each individual patient presents with a different gastric cancer cell type, degree of differentiation, malignant potential of tumors, and depth of invasion, and therefore, a careful approach is essential in selecting anticancer drugs. Ott et al. 39 performed baseline PET scans and additional PET scans after 2 to 3 cycles of chemotherapy, and they proposed that the therapeutic effects of anticancer drugs can be determined by comparison of these two scans. 39 Recently, many reports have suggested that the efficacy of therapeutic options can be determined by evaluating not only changes in size, but also changes in lesion metabolism.
Therefore, the role of FDG PET/CT in management of gastric cancer will continue to expand in the future. 
2) Lymphadenectomy

3) Combined resection
Combined resection of involved organs can be performed in cases showing direct invasion into the adjacent organs, [48] [49] [50] [51] [52] [53] [54] [55] [56] [57] [58] gastric cancers in the greater curvature with muscularis propria invasion, suspected splenic hilar lymph node involvement, 59-62 suspected distant metastasis, [63] [64] [65] [66] and in patients undergoing palliative surgery.
4) Reconstruction
Only a few studies have compared the differences between postoperative reconstruction methods. A few studies have compared Billroth-I and Billroth-II and have reported that the 2 types of anastomosis did not show significant differences with regard to therapeutic performance or difficulty in ingestion. 67, 68 Additionally, Roux-en-Y gastric bypass might be superior to Billroth-I anastomosis in terms of postoperative bilious reflux. [91] [92] [93] [94] [95] [96] However, according to a Cochrane review, there are no randomized controlled trials comparing endoscopic therapy and surgery. 97 Theoretically, the indication for endoscopic therapy is EGC without risk of lymph node metastasis. However, it is impossible to diagnose lymph node metastases accurately before treatment.
Therefore, indications for endoscopic treatment were defined based on the analysis of surgical date of lymph node metastasis. 
Expanded indications
With the development of ESD techniques, there have been attempts to extend the indications of endoscopic resection. 96, 103, 104 Expanded indications include (1) well or moderately differentiated adenocarcinoma in the mucosal layer without an ulcer regardless of the size, (2) well or moderately differentiated adenocarcinoma measuring less than 3 cm in the mucosal layer with ulcer, (3) small (less than 2 cm) intramucosal cancer with undifferentiated histology, and (4) well or moderately differentiated adenocarcinoma with minute submucosal invasion (≤500 μm, SM1).
Followup
The National Comprehensive Cancer Network guidelines recommend that follow-up after gastric cancer treatment should be conducted every 3 to 6 months for the first three years after R0 resection. For 3 to 5 years, the follow-up interval is 6 months, and there it is yearly. The guideline states that complete blood count, biochemical tests, radiologic studies, and endoscopy can be performed if they are clinically necessary. 105 The recurrence rate after endoscopic therapy for EGC is 3.3% to 14.0%. It is recommended that patients should undergo an endoscopic follow-up at least annually because of the risk of missing multiple synchronous cancers.
Recommendation: Endoscopic follow-up is recommended at least annually after endoscopic therapy for early gastric cancer (Rec- 
119-122
A recent meta-analysis of randomized trials showed that combination chemotherapy significantly improves the survival, compared to single chemotherapy or best supportive care alone. 115 First-line palliative chemotherapy with a two-drug combination of fluoropyrimidines and platinum is preferred for patients with advanced or metastatic disease. Three-drug combination chemotherapy with docetaxel or epirubicin should be reserved for medically fit patients with a good performance status.
Recently, molecular targeted agents such as trastuzumab, bevacizumab, cetuximab, and lapatinib have been tested with the standard chemotherapy for recurrent and metastatic gastric cancers.
Based on the results of the ToGA study, which showed a significant improvement in the median overall survival (13.5 vs. 11.1 months) with the addition of trastuzumab to chemotherapy (5-FU or capecitabine and cisplatin), trastuzumab in combination with chemotherapy is recommended for patients having HER2 overexpression or amplification (HER2 IHC 3+ or HER2 IHC 2+ with FISH/SISH+). 123 However, the addition of either bevacizumab, 124 cetuximab, 125 or lapatinib 126 to chemotherapy failed to show survival benefit in recent phase III clinical trials. 
Radiation therapy 1. Neoadjuvant radiation therapy
Neoadjuvant radiation therapy can be performed before surgery to increase the possibility of performing radical resection in patients with locally advanced gastric cancer. To date, there have been three randomized controlled trials regarding neoadjuvant radiation therapy. Zhang et al. 129 reported a significant increases in the 5-and 10-year overall survival and resection rates in neoadjuvant radiation therapy group compared to surgery alone group, when 370 patients with gastric adenocarcinomas located in the gastric cardia were compared. Skoropad et al. 130, 131 reported that neoadjuvant radiation therapy tended to increase survival rates among patients with preoperatively positive lymph node metastases or clinical T3 or higher stage.
Recommendation: Neoadjuvant radiation therapy may be considered in patients with locally advanced gastric cancer (Recommendation Grade 2, Evidence Level C). adjuvant chemoradiotherapy reduced the local recurrence rate after D1 lymph node dissection, but no difference was observed after D2 lymph node dissection. Hence, a randomized phase 3 clinical study is needed to determine the effects of adjuvant chemoradiotherapy after extended lymph node dissection.
Adjuvant radiation therapy
Recommendation: Chemoradiotherapy may be considered as a postoperative adjuvant therapy for radically resected gastric cancer patients (Recommendation Grade 2, Evidence Level C).
Although it is not possible to obtain a curative effect, palliative radiation therapy can be used to alleviate patients' symptoms and to increase the quality of life of patients. Palliative radiation therapy can be applied to reduce severe bleeding or difficulty in swallowing caused by stomach cancers and severe pain due to metastasis to other organs (e.g., brain, bone, and abdomen).
Pathologic evaluation Group of Korean Society of Pathologists. 135 For frozen section or tissue banking, the use of a fresh unfixed tissue is recommended.
Pathologic diagnosis of gastric cancer
The World Health Organization classification 136 is used for histological classification of gastric cancers, and Lauren classification 137 can be added in it. If histological classification is difficult, immunohistochemical or histochemical staining will be helpful. Tubular adenocarcinomas should be classified according to the grade of differentiation, for which the 2-, 3-, or 4-tier grading system can be used. Generally, the 3-tier grading system is used. 
Pathologic evaluation of lymph node metastasis
Accurate pathologic evaluation of lymph nodes is mandatory for cancer staging. As many lymph nodes as possible should be microscopically examined in the radically resected specimens. The pN staging is determined using the conventional hematoxylin and eosin stain. Tumor staging is based on the AJCC staging system. 
